For the quarter ending 2025-09-30, RNTX has $53,706K in assets. $7,516K in debts. $4,048K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 4,048 | 5,722 | ||
| Prepaid expenses and other current assets | 1,126 | 880 | ||
| Total current assets | 5,174 | 6,602 | ||
| Property and equipment, net | 0 | 1 | ||
| Goodwill | 6,330 | 6,330 | ||
| Intangible assets | 42,200 | 42,200 | ||
| Other non-current assets | 2 | 2,346 | ||
| Total assets | 53,706 | 57,479 | ||
| Accounts payable | 4,123 | 6,028 | ||
| Accrued expenses and other current liabilities | 1,621 | 1,666 | ||
| Total current liabilities | 5,744 | 7,694 | ||
| Deferred tax liability | 1,772 | 1,772 | ||
| Other long-term liability | 0 | 0 | ||
| Total liabilities | 7,516 | 9,466 | ||
| Convertible preferred stock, 0.001 par value, 5,000,000 shares authorized at september 30, 2025 and at december 31, 2024 24,610 shares issued and 12,232 shares outstanding at september 30, 2025 and at december 31, 2024 | 45,005 | 45,005 | ||
| Common stock, 0.001 par value 100,000,000 shares authorized at september 30, 2025 and at december 31, 2024 25,140,092 shares and 21,666,012 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 111 | 109 | ||
| Common stock subscribed | - | 22 | ||
| Additional paid-in capital | 370,422 | 366,644 | ||
| Accumulated other comprehensive loss | -44 | -44 | ||
| Accumulated deficit | -369,304 | -363,723 | ||
| Total liabilities, convertible preferred stock and stockholders' equity | 53,706 | 57,479 | ||
Rein Therapeutics, Inc. (RNTX)
Rein Therapeutics, Inc. (RNTX)